Feline infectious peritonitis (FIP) is a highly fatal systemic disease in cats, caused by feline coronavirus (FCoV) infection. FCoV usually has little clinical signifi cance; however, a mutation of this avirulent virus (feline enteric coronavirus) to a virulent type (FIP virus) can lead to FIP incidence. It is diffi cult to diagnose FIP, since the viruses cannot be distinguished using serological or virological methods. Recently, genetic techniques, such as RT-PCR, have been conducted for FIP diagnosis. In this chapter, the reliability of RT-PCR and procedures used to determine FCoV infection as part of antemortem FIP diagnosis is described.
Introduction
Feline infectious peritonitis (FIP) is an immune-mediated progressive and systemic infectious disease occurring in domestic cats and wild felids, and caused by infection with feline coronavirus (FCoV), a single-stranded RNA virus, which has been classifi ed as Alphacoronavirus along with canine coronavirus (CCoV) and transmissible gastroenteritis virus [ 1 , 2 ] . FCoV is transmitted by the fecal-oral route and usually causes a mild to inapparent enteritis [ 2 ] . FIP is considered to be induced by a virulent mutant (FIP virus; FIPV) of this enteric FCoV (feline enteric coronavirus; FECV) [ 2 , 3 ] . The incidence of FIP is generally as low as 1-3 % in FCoV-infected cats, though it varies depending on age, breed, environment, and superinfection with other viruses [ 2 , 4 -6 ] .
It is divided into two basic clinical forms, effusive FIP, in which effusion is observed in the body cavity, and non-effusive FIP, in which multiple pyogranuloma lesions are observed, though differences in lesions are infl uenced by individual immunity [ 7 ] . Furthermore, there are two types (I and II) of FCoV, with FCoV type II considered to arise by a recombination of FCoV type I and CCoV [ 8 -10 ] . Based on genetic and serological investigations, FCoV type I is overwhelmingly dominant as compared to type II and mixed infection with both types is not rare [ 11 -14 ] .
Since FIPV and FECV cannot be fully distinguished using serological methods, it is generally diffi cult to diagnose FIP [ 1 ] . Therefore, other laboratory fi ndings such as hematology and serum biochemistry examinations [ 15 , 16 ] have been referred to FIP diagnosis . Recently, it has been stated that demonstration of FCoV RNA by RT-PCR is one of the most reliable diagnostic indicators of FIP in suspected cases [ 7 , 17 ] . However, FIPV and FECV are not necessarily distinguished with certainty, and the reliability of RT-PCR for FIP diagnosis depends largely on the test specimens as well as rearing environment of the affected cat.
Test specimens used with FCoV RT-PCR for FIP diagnosis include body cavity fl uid (ascitic and pleural effusions), blood, cerebrospinal fl uid (CSF), and tissues. As shown in Table 1 , effusion is the most suitable, and FCoV RNA detection provides highly sensitive and specifi c diagnosis [ 1 , 17 -19 ] . When using CSF, RNA detection can also give a highly specifi c diagnosis. However, the absence of FIP cannot be generally concluded based on negative results, because small amounts of the virus may exist in CSF from FIP cases [ 1 , 20 , 21 ] . Even in non-FIP and healthy carriers, RNA may be detected in blood for several months after FECV infection [ 22 , 23 ] . Of note, associated RNA is frequently detected in blood from FCoV-endemic multi-cat households. Thus, the reliability of RT-PCR -positive results obtained from a blood specimen is dependent on the rearing environment [ 23 -25 ] . In contrast, FIP may be excluded when a blood specimen is RT-PCR negative, because the RNA detection sensitivity is relatively high with blood from FIP cases [ 17 , 23 , 26 , 27 ] . RNA detection sensitivity varies among tissues, i.e., higher in the liver and spleen, and lower in the kidneys and heart [ 28 -30 ] . Tissue samples generally contain blood, which compromises the reproducibility of FIP diagnosis with RT-PCRpositive tissues [ 1 , 29 ] .
In this chapter, three RT-PCR techniques generally employed for FIP diagnosis in Japan are outlined in regard to their usefulness for antemortem diagnosis. 
Materials
Three FCoV RT-PCR primer sets are recommended for FIP diagnosis , as shown in Table 2 . One targets the 3′-untranslated region (3′-UTR) (P205-P211 primer set) [ 17 ] for FIP screening. This region is the fi rst choice for RT-PCR , because it is highly conserved among Alphacoronavirus and allows sensitive FCoV RNA detection . A second-round (nested) PCR primer set (P276-P204) is also available to check the specifi city of the RT-PCR result.
To confi rm a positive RT-PCR reaction, a subsequent RT-PCR assay is recommended using a primer set that recognizes subgenomic mRNA of the M gene (212-1179 primer set) [ 27 ] (Table 2 ). Since detection of this gene indicates viral replication, FIPV, which has increased microphage infectivity, is able to be detected with high specifi city. This RT-PCR technique is more useful for specimens other than effusion samples and CSF. However, in our experience, mRNA detection tends to be less sensitive than 3′-UTR RT-PCR.
To determine the type of cases shown positive with the above RT-PCR assays, a primer set targeting the S gene should be used for a multiplex RT-PCR (Iffs-Icfs-Iubs primer set) ( Table 2 ) [ 31 ] . For negative cases shown by RT-PCR, nested PCR should be conducted using nIffl e-nIcfs-nIubs primer set ( see Note 1 ). 4. DNase-and RNase-free water (Invitrogen).
Primer Set for RT-PCR
5. DNase-and RNase-free ethanol, 99.5 %(V/V) (Wako). 
Reagent for

RNase inhibitor, 40 U/mL (Promega).
3. Primers, 10 μM (shown in Table 2 ).
1. DNase-and RNase-free water (invitrogen).
2. AmpliTaq Gold DNA polymerase, 5 U/mL, with 10× PCR buffer, MgCl 2 solution (25 mM), and dNTP mix (2 mM each) (Applied Biosystems).
1. Tris-borate-EDTA (TBE) buffer, pH 8.3 (TaKaRa).
Agarose-LE powder (Ambion).
3. 6× Gel loading dye, containing bromophenol blue and orange G (Toyobo).
4. 100 bp DNA ladder marker, with loading dye (Toyobo).
1. Ethidium bromide (EtBr), 10 mg/mL (invitrogen).
Distilled water (for diluting EtBr stock solution), not necessarily
DNase-and RNase-free water. 
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Methods
Viral RNA is extracted from effusion, serum, plasma, whole blood, cerebrospinal fl uid (CSF), and tissue (biopsy) specimens using a QIAamp Viral RNA Mini Kit, QIAamp Blood RNA Mini Kit, or RNeasy Mini Kit (Qiagen), according to the manufacturer's instructions ( see Notes 2 -6 ).
Next, reaction mixtures for RT-PCR are prepared, as shown in Table 3 . Five microliters of the template (purifi ed RNA) is added to the reaction mixture and subjected to amplifi cation in a thermal cycler (Table 4 ) ( see Notes 7 -9 ). Reaction mixtures for the nested PCR assay are then prepared, as shown in Table 5 . Five microliters of the RT-PCR product diluted 100 times with DNase-and RNase-free water is added to the reaction mixtures, and then subjected to amplifi cation (Table 6 ) ( see Notes 7 -9 ).
RNA Extraction and Purifi cation 3.2 RT-PCR
Five microliters of the PCR product is then added to 6× gel loading dye at a 1/6 volume ratio and electrophoresed with TBE buffer at 100 V for 35 min on a 2 % agarose gel at room temperature.
Following electrophoresis, the gel is immersed into 10 mg/mL of EtBr solution. After staining for 30-40 min, the gel is photographed under UV illumination ( see Notes 10 -12 ). 
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Notes
For FCoV RT-PCR implementation and FIP diagnosis , the following points should be noted.
1. False-negative results may be obtained when no viral RNA is detected with the indicated primers because of viral mutations. This is more likely to occur with primers targeting the S gene.
2. Care should be exercised to prevent coagulation of whole blood samples. EDTA is suitable as an anticoagulant, while heparin is not recommended, because it may cause coagulation during transportation.
3. Care should be exercised to prevent blood contamination during CSF sampling, as viral RNA may be contained in blood even in non-FIP cases.
4. Care should be exercised during sampling and transportation, because RNA is fragile, and disposable DNase-and RNase-free sampling containers should be used. Collected samples should be immediately transported to a laboratory in a refrigerated state.
5. DNase-and RNase-free phosphate buffer saline (PBS) should be used to increase sample volume before testing as needed.
6. Effusion, serum, and plasma specimens should be centrifuged with a refrigerated centrifuge prior to purifi cation with the QIAamp Viral RNA Mini Kit, and the resulting supernatants should then be purifi ed.
7. Reaction mixtures should be prepared and dispensed on ice.
8. PCR is highly sensitive and may yield false-positive results when contaminated by even a small amount of nucleic acid. Thus, reaction mixtures should be prepared and dispensed in clean environments, such as a clean bench, and only test results obtained by skilled experimenters are considered to be reliable.
9. Only DNase-and RNase-free instruments, such as test tubes and pipette chips, should be used.
10. Since EtBr is deactivated by light, its solution should be stored in a light-shielded condition.
11. Care should be exercised in handling EtBr for gel staining, because EtBr is toxic to humans. It should be also detoxifi ed in appropriate manners, such as activated carbon adsorption, reductive decomposition, and oxidative decomposition, before disposal. A detoxifying reagent is commercially available (EtBr destroyer, Wako).
12. Care should be exercised in regard to UV irradiation during gel observation, as UV may damage eyes and skin.
